SANA

Over the past six months, Sana Biotechnology's stock experienced several notable events: an 8.41% increase on April 13, 2026, followed by an 8.43% drop on May 11, 2026. On July 13, 2026, a New England Journal of Medicine publication on hypoimmune-modified islet cell transplantation led to a 5.45% stock decrease. The company's Second Quarter 2026 Financial Results and Business Updates on August 10, 2026, resulted in a 4.99% increase. In mid-August 2026, BofA lowered its price target from $7 to $6 while maintaining a Buy rating. On September 1, 2026, an announcement of presentations at investor conferences led to a 1.57% increase. News broke on September 8, 2026, about plans for cell therapy for 10 million with type 1 diabetes. A bearish signal emerged on September 14, 2026, as the 10-day moving average crossed below the 50-day moving average. Regulatory delays in China for the SG293 program pushed expected clinical data to the first half of 2027, contributing to an approximate 20% stock loss since June 30, 2026.